Paul Hourd

739 total citations
23 papers, 528 citations indexed

About

Paul Hourd is a scholar working on Biomedical Engineering, Molecular Biology and Physiology. According to data from OpenAlex, Paul Hourd has authored 23 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Biomedical Engineering, 13 papers in Molecular Biology and 8 papers in Physiology. Recurrent topics in Paul Hourd's work include 3D Printing in Biomedical Research (13 papers), Pluripotent Stem Cells Research (12 papers) and Biomedical Ethics and Regulation (8 papers). Paul Hourd is often cited by papers focused on 3D Printing in Biomedical Research (13 papers), Pluripotent Stem Cells Research (12 papers) and Biomedical Ethics and Regulation (8 papers). Paul Hourd collaborates with scholars based in United Kingdom, Sweden and India. Paul Hourd's co-authors include David Williams, Robert J. Thomas, Amit Chandra, Yang Liu, Patrick Ginty, Nicholas Medcalf, Joel Segal, Elizabeth Ratcliffe, Paul Conway and Andrew Hope and has published in prestigious journals such as Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences, Journal of Biotechnology and Biotechnology Letters.

In The Last Decade

Paul Hourd

23 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Hourd United Kingdom 13 290 243 110 98 90 23 528
Emily J Culme-Seymour United Kingdom 10 160 0.6× 200 0.8× 120 1.1× 140 1.4× 115 1.3× 17 485
Daniel Naveed Tavakol United States 14 317 1.1× 152 0.6× 78 0.7× 110 1.1× 51 0.6× 29 582
Bo Kara United Kingdom 13 219 0.8× 368 1.5× 242 2.2× 181 1.8× 38 0.4× 19 724
Nicholas Medcalf United Kingdom 12 210 0.7× 125 0.5× 30 0.3× 74 0.8× 73 0.8× 28 443
Thomas R.J. Heathman United Kingdom 16 369 1.3× 376 1.5× 321 2.9× 257 2.6× 44 0.5× 22 850
Mark McCall United Kingdom 6 108 0.4× 142 0.6× 86 0.8× 75 0.8× 55 0.6× 11 298
Luca Pontiggia Switzerland 17 190 0.7× 190 0.8× 89 0.8× 142 1.4× 45 0.5× 34 818
Ross Fitzsimmons Canada 7 116 0.4× 302 1.2× 178 1.6× 103 1.1× 39 0.4× 8 596
Christabella Adine Singapore 9 171 0.6× 89 0.4× 82 0.7× 55 0.6× 129 1.4× 10 361
Tatjana Schilling Germany 14 184 0.6× 387 1.6× 242 2.2× 183 1.9× 45 0.5× 21 848

Countries citing papers authored by Paul Hourd

Since Specialization
Citations

This map shows the geographic impact of Paul Hourd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Hourd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Hourd more than expected).

Fields of papers citing papers by Paul Hourd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Hourd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Hourd. The network helps show where Paul Hourd may publish in the future.

Co-authorship network of co-authors of Paul Hourd

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Hourd. A scholar is included among the top collaborators of Paul Hourd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Hourd. Paul Hourd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sebastian, Sujith, Paul Hourd, Amit Chandra, David Williams, & Nicholas Medcalf. (2019). The Management of Risk and Investment in Cell Therapy Process Development: A Case Study for Neurodegenerative Disease. Regenerative Medicine. 14(5). 465–488. 2 indexed citations
2.
3.
Phillips, Wendy, Nicholas Medcalf, Kenny Dalgarno, et al.. (2017). Redistributed Manufacturing in Healthcare: Creating New Value through Disruptive Innovation. UWE Research Repository (UWE Bristol). 10 indexed citations
4.
Mitchell, Peter, Elizabeth Ratcliffe, Paul Hourd, David Williams, & Robert J. Thomas. (2014). A Quality-by-Design Approach to Risk Reduction and Optimization for Human Embryonic Stem Cell Cryopreservation Processes. Tissue Engineering Part C Methods. 20(12). 941–950. 15 indexed citations
5.
Hourd, Paul, Patrick Ginty, Amit Chandra, & David Williams. (2014). Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy. 16(8). 1033–1047. 50 indexed citations
6.
Naing, May Win, Daniel Gibson, Paul Hourd, et al.. (2014). Improving umbilical cord blood processing to increase total nucleated cell count yield and reduce cord input wastage by managing the consequences of input variation. Cytotherapy. 17(1). 58–67. 13 indexed citations
7.
8.
Hourd, Paul, Amit Chandra, Patrick Ginty, et al.. (2014). Qualification of Academic Facilities for Small-Scale Automated Manufacture of Autologous Cell-Based Products. Regenerative Medicine. 9(6). 799–815. 12 indexed citations
9.
Hourd, Paul, et al.. (2013). Mesenchymal Stem Cell Isolation from Human Umbilical Cord Tissue: Understanding and Minimizing Variability in Cell Yield for Process Optimization. Biopreservation and Biobanking. 11(5). 291–298. 23 indexed citations
10.
Williams, David, Robert J. Thomas, Paul Hourd, et al.. (2012). Precision manufacturing for clinical-quality regenerative medicines. Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences. 370(1973). 3924–3949. 45 indexed citations
11.
Ratcliffe, Elizabeth, et al.. (2012). Application of Response Surface Methodology to Maximize the Productivity of Scalable Automated Human Embryonic Stem Cell Manufacture. Regenerative Medicine. 8(1). 39–48. 12 indexed citations
12.
Ginty, Patrick, et al.. (2011). Regenerative Medicine, Resource and Regulation: Lessons Learned from the Remedi Project. Regenerative Medicine. 6(2). 241–253. 14 indexed citations
13.
Hourd, Paul, et al.. (2010). Achieving Reimbursement for Regenerative Medicine Products in the USA. Regenerative Medicine. 5(3). 463–469. 12 indexed citations
14.
Thomas, Robert J., Andrew Hope, Paul Hourd, et al.. (2009). Automated, serum-free production of CTX0E03: a therapeutic clinical grade human neural stem cell line. Biotechnology Letters. 31(8). 1167–1172. 33 indexed citations
15.
Liu, Yang, Paul Hourd, Amit Chandra, & David Williams. (2009). Human cell culture process capability: a comparison of manual and automated production. Journal of Tissue Engineering and Regenerative Medicine. 4(1). n/a–n/a. 49 indexed citations
16.
Thomas, Robert J., Paul Hourd, & David Williams. (2008). Application of process quality engineering techniques to improve the understanding of the in vitro processing of stem cells for therapeutic use. Journal of Biotechnology. 136(3-4). 148–155. 54 indexed citations
17.
Hourd, Paul & David Williams. (2008). Results from an exploratory study to identify the factors that contribute to success for UK medical device small- and medium-sized enterprises. Proceedings of the Institution of Mechanical Engineers Part H Journal of Engineering in Medicine. 222(5). 717–735. 8 indexed citations
18.
Han, Zhenyu, et al.. (2008). On the process capability of the solid free-form fabrication: A case study of scaffold moulds for tissue engineering. Proceedings of the Institution of Mechanical Engineers Part H Journal of Engineering in Medicine. 222(3). 377–391. 3 indexed citations
19.
Thomas, Robert J., Amit Chandra, Yang Liu, et al.. (2007). Manufacture of a human mesenchymal stem cell population using an automated cell culture platform. Cytotechnology. 55(1). 31–39. 46 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emily J Culme-Seymour Breakdown of academic impact, for papers by Daniel Naveed Tavakol Breakdown of academic impact, for papers by Bo Kara Breakdown of academic impact, for papers by Nicholas Medcalf Breakdown of academic impact, for papers by Thomas R.J. Heathman Breakdown of academic impact, for papers by Mark McCall Breakdown of academic impact, for papers by Luca Pontiggia Breakdown of academic impact, for papers by Ross Fitzsimmons Breakdown of academic impact, for papers by Christabella Adine Breakdown of academic impact, for papers by Tatjana Schilling
Rankless by CCL
2026